On July 26, 2022 BroadenBio reported the company received the new drug clinical trial approval notice for the Class I investigational new drug BB102 from the Center of Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on July 26th, 2022 (Press release, BroadenBio, JUL 26, 2022, View Source [SID1234640199]). The first-in-human Phase 1 clinical trials for advanced solid tumors in China will be initiated soon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BB102 is an innovative small molecule kinase inhibitor discovered and being developed by BroadenBio for the treatment of advanced solid tumors driven by abnormal oncogenic genes. Besides its novel mechanism of action, high selectivity, good safety, and over advantages, BB102 shows promising efficacy to mutation-driven tumors, and is expected to benefit more cancer patients.